Table 2.
Immunoexpression of DFF40*, DFF45**, and BCL2*** in endometrial cancers in relation to histological type and study groups A and B
| Low and moderate-grade endometroid cancer (Group A) | pA | Non-endometrioid and high-grade endometroid endometrial cancer (Group B) | pB | |||||
|---|---|---|---|---|---|---|---|---|
| Tumor histology | EAC-G1$ N = 90 |
EAC-G2$$ N = 125 |
Carcinosarcomas N = 31 |
Serosus tumor N = 22 |
Clear cell tuor N = 25 |
EAC-G3$$$ N = 49 |
||
| DFF40* | ||||||||
| High | 31 (34.44%) | 28 (22.40%) | 0.143 | 5 (16.13%) | 2 (9.09%) | 1 (4.00%) | 4 (8.16%) | 0.754 |
| Low | 33 (36.67%) | 52 (41.60%) | 6 (19.35%) | 3 (13.64%) | 6 (24.00%) | 11 (22.45%) | ||
| Negative | 26 (28.89%) | 45 (36.00%) | 20 (64.52%) | 17 (77.27%) | 18 (72.00%) | 34 (69.39%) | ||
| pAB < 0.001# | ||||||||
| DFF45** | ||||||||
| High | 1 (1.11%) | 0 (0.00%) | 0.409 | 1 (3.22%) | 0 (0.00%) | 0 (0.00%) | 2 (4.08%) | 0.935 |
| Low | 7 (7.78%) | 13 (10.40%) | 3 (9.68%) | 2 (9.09%) | 3 (12.00%) | 10 (20.41%) | ||
| Negative | 82 (9.11%) | 112 (89.6%) | 27 (87.10%) | 20 (90.91%) | 22 (88.00%) | 37 (75.51%) | ||
| pAB = 0.101 | ||||||||
| Bcl-2*** | ||||||||
| High | 29 (32.22%) | 44 (35.20%) | 0.523 | 2 (6.45%) | 1 (4.55%) | 1 (4.00%) | 5 (10.21%) | 0.187 |
| 4 (12.90%) | 4 (18.18%) | 3 (12.00%) | ||||||
| Low | 34 (37.78%) | 38 (30.40%) | 16 (32.65%) | |||||
| Negative | 27 (30.00%) | 43 (34.40%) | 25 (80.65%) | 17 (77.27%) | 21 (84.00%) | 28 (57.14%) | ||
| pAB < 0.001# | ||||||||
pA – chi-squared test in Group A; pB – chi-squared test in Group B; pAB – chi-squared test between Group A and Group B; $endometrial adenocarcinoma grade 1; $$endometrial adenocarcinoma grade 2; $$$endometrial adenocarcinoma grade 3; *DFF40 – DNA fragmentation factor 40; **DFF45 – DNA fragmentation factor 45; ***BCL2 – B-cell lymphoma 2